FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2222151010> ?p ?o ?g. }

• W2222151010 endingPage "1725" @default.
• W2222151010 startingPage "1720" @default.
• W2222151010 abstract "Concurrent chemoradiation therapy (CRT) is the current standard of care for patients with locally advanced lung adenocarcinoma; however, little has been reported about the impact of epidermal growth factor receptor (EGFR) mutation on CRT efficacy.From 2006 to 2013, we retrospectively screened 104 unresectable stage III adenocarcinoma patients who were examined for EGFR mutation status and received definitive concurrent CRT consisting of platinum doublet chemotherapy in first-line setting and compared the clinical outcomes and recurrence patterns according to mutation status.Among 104 patients, EGFR mutation was detected in 29 (28%). The overall response rate did not differ between EGFR-mutant and wild-type patients (72.4% versus 72.0%, p = 0.607). The median progression-free survival in concurrent CRT was significantly shorter in EGFR-mutant patients than in wild-type patients (9.8 [95% confidence interval, CI: 7.6-19.0] versus 16.5 [95% CI: 11.8-19.9] months, p = 0.041). The 2-year recurrence-free survival rate was 7.7% and 28.1% in EGFR-mutant and wild-type patients, respectively (p = 0.028). Distant metastases were more frequently identified as the first recurrence site in EGFR-mutant patients than in wild-type patients (76% versus 40%, p = 0.001). The brain was the most often affected site in EGFR-mutant patients (35%). However, locoregional recurrence was less common in EGFR-mutant patients than in the wild-type population (14% versus 35%, p = 0.027). Overall survival was similar between EGFR-mutant and wild-type patients (51.1 [95% CI: 28.2-70.2] versus 42.9 [95% CI: 35.3 to not available] months, p = 0.637). Among the EGFR wild-type population who were examined for Kras mutation, Kras-mutant patients had significantly worse overall survival than Kras wild-type patients (21.6 versus 49.8 months, p = 0.024).Concurrent CRT resulted in shorter progression-free survival in EGFR-mutant stage III adenocarcinoma patients than in wild-type patients, mainly because of distant metastasis relapse, regardless of better local control. Because of these distinct biological features, a different strategy, including EGFR-tyrosine kinase inhibitors for EGFR-mutant locally advanced adenocarcinoma patients receiving definitive CRT may be needed." @default.
• W2222151010 created "2016-06-24" @default.
• W2222151010 creator A5000653374 @default.
• W2222151010 creator A5002327424 @default.
• W2222151010 creator A5007279449 @default.
• W2222151010 creator A5016131935 @default.
• W2222151010 creator A5020608796 @default.
• W2222151010 creator A5022022857 @default.
• W2222151010 creator A5029393521 @default.
• W2222151010 creator A5035163164 @default.
• W2222151010 creator A5038749740 @default.
• W2222151010 creator A5053773586 @default.
• W2222151010 creator A5060609402 @default.
• W2222151010 creator A5065196329 @default.
• W2222151010 creator A5080938148 @default.
• W2222151010 creator A5086229141 @default.
• W2222151010 creator A5088647389 @default.
• W2222151010 date "2015-12-01" @default.
• W2222151010 modified "2023-10-18" @default.
• W2222151010 title "EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma" @default.
• W2222151010 cites W1944220675 @default.
• W2222151010 cites W1969875009 @default.
• W2222151010 cites W1975509166 @default.
• W2222151010 cites W1983787599 @default.
• W2222151010 cites W1989595177 @default.
• W2222151010 cites W1991874467 @default.
• W2222151010 cites W2017813339 @default.
• W2222151010 cites W2028315898 @default.
• W2222151010 cites W2028621244 @default.
• W2222151010 cites W2043696829 @default.
• W2222151010 cites W2044191519 @default.
• W2222151010 cites W2069814286 @default.
• W2222151010 cites W2085280721 @default.
• W2222151010 cites W2114642822 @default.
• W2222151010 cites W2119340070 @default.
• W2222151010 cites W2132157071 @default.
• W2222151010 cites W2138297714 @default.
• W2222151010 cites W2139236349 @default.
• W2222151010 cites W2145653040 @default.
• W2222151010 cites W2152261578 @default.
• W2222151010 cites W2161821474 @default.
• W2222151010 cites W2165459839 @default.
• W2222151010 cites W2166084034 @default.
• W2222151010 doi "https://doi.org/10.1097/jto.0000000000000675" @default.
• W2222151010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26743855" @default.
• W2222151010 hasPublicationYear "2015" @default.
• W2222151010 type Work @default.
• W2222151010 sameAs 2222151010 @default.
• W2222151010 citedByCount "53" @default.
• W2222151010 countsByYear W22221510102016 @default.
• W2222151010 countsByYear W22221510102017 @default.
• W2222151010 countsByYear W22221510102018 @default.
• W2222151010 countsByYear W22221510102019 @default.
• W2222151010 countsByYear W22221510102020 @default.
• W2222151010 countsByYear W22221510102021 @default.
• W2222151010 countsByYear W22221510102022 @default.
• W2222151010 countsByYear W22221510102023 @default.
• W2222151010 crossrefType "journal-article" @default.
• W2222151010 hasAuthorship W2222151010A5000653374 @default.
• W2222151010 hasAuthorship W2222151010A5002327424 @default.
• W2222151010 hasAuthorship W2222151010A5007279449 @default.
• W2222151010 hasAuthorship W2222151010A5016131935 @default.
• W2222151010 hasAuthorship W2222151010A5020608796 @default.
• W2222151010 hasAuthorship W2222151010A5022022857 @default.
• W2222151010 hasAuthorship W2222151010A5029393521 @default.
• W2222151010 hasAuthorship W2222151010A5035163164 @default.
• W2222151010 hasAuthorship W2222151010A5038749740 @default.
• W2222151010 hasAuthorship W2222151010A5053773586 @default.
• W2222151010 hasAuthorship W2222151010A5060609402 @default.
• W2222151010 hasAuthorship W2222151010A5065196329 @default.
• W2222151010 hasAuthorship W2222151010A5080938148 @default.
• W2222151010 hasAuthorship W2222151010A5086229141 @default.
• W2222151010 hasAuthorship W2222151010A5088647389 @default.
• W2222151010 hasBestOaLocation W22221510101 @default.
• W2222151010 hasConcept C104317684 @default.
• W2222151010 hasConcept C121608353 @default.
• W2222151010 hasConcept C126322002 @default.
• W2222151010 hasConcept C143065580 @default.
• W2222151010 hasConcept C143998085 @default.
• W2222151010 hasConcept C146357865 @default.
• W2222151010 hasConcept C151730666 @default.
• W2222151010 hasConcept C207583985 @default.
• W2222151010 hasConcept C2776694085 @default.
• W2222151010 hasConcept C2779438470 @default.
• W2222151010 hasConcept C2781182431 @default.
• W2222151010 hasConcept C2908647359 @default.
• W2222151010 hasConcept C44249647 @default.
• W2222151010 hasConcept C501734568 @default.
• W2222151010 hasConcept C55493867 @default.
• W2222151010 hasConcept C71924100 @default.
• W2222151010 hasConcept C86803240 @default.
• W2222151010 hasConcept C90924648 @default.
• W2222151010 hasConcept C99454951 @default.
• W2222151010 hasConceptScore W2222151010C104317684 @default.
• W2222151010 hasConceptScore W2222151010C121608353 @default.
• W2222151010 hasConceptScore W2222151010C126322002 @default.
• W2222151010 hasConceptScore W2222151010C143065580 @default.
• W2222151010 hasConceptScore W2222151010C143998085 @default.

• next